Education
About Us
Working with TipRanks
Follow Us
Valneva SE (GB:0OB3)
LSE:0OB3
Earnings Data
Report Date
Mar 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.21Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Valneva reported overall revenue growth and made significant strides in regulatory achievements and strategic partnerships. However, the company faced challenges with an operating loss, the suspension of IXCHIQ in the U.S., and decreased sales for some products. The uncertainty around the Zika vaccine candidate also adds to future concerns.Company Guidance
Revenue Growth and Financial Management
Total revenues reached EUR 127 million at the 9-month time point, a substantial growth of almost 9%. Operating cash burn significantly reduced, resulting in a cash position of more than EUR 140 million. Successfully completed debt refinancing, enhancing financial flexibility.
Product and Regulatory Achievements
Secured additional marketing authorizations for IXCHIQ in the U.K. and Brazil. Completed vaccinations in the VALOR Phase III Lyme disease study. Reported positive data for chikungunya vaccine IXCHIQ and the second-generation Zika vaccine candidate, VLA1601.
Strategic Partnerships and Agreements
Announced an exclusive vaccine marketing and distribution agreement for Germany with CSL Seqirus. Found a new partner, Pharmakon, for financial support.
IXIARO Sales Growth
IXIARO sales reached EUR 74.3 million, increasing 12.5% over the prior year, driven by sales to the U.S. Department of Defense and increased sales in some European countries.
GB:0OB3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0OB3 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 20, 2025 | €3.78 | €3.92 | +3.70% |
Aug 12, 2025 | €3.77 | €3.94 | +4.51% |
May 07, 2025 | €2.90 | €2.92 | +0.69% |
Mar 20, 2025 | €3.20 | €3.36 | +5.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva SE (GB:0OB3) report earnings?
Valneva SE (GB:0OB3) is schdueled to report earning on Mar 19, 2026, TBA (Confirmed).
What is Valneva SE (GB:0OB3) earnings time?
Valneva SE (GB:0OB3) earnings time is at Mar 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Valneva SE stock?
The P/E ratio of Valneva is N/A.
What is GB:0OB3 EPS forecast?
GB:0OB3 EPS forecast for the fiscal quarter 2025 (Q4) is -0.14.